Titre:
  • Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.
Auteur:Domenech, Carine; Suciu, Stefan; De Moerloose, Barbara; Mazingue, Françoise; Plat, Geneviève; Ferster, Alina; Uyttebroeck, Anne; Sirvent, Nicolas; Lutz, Patrick; Yakouben, Karima; Munzer, Martine; Rohrlich, Pierre; Plantaz, Dominique; Millot, Frédéric; Philippet, Pierre; Dastugue, Nicole; Girard, Sandrine; Cavé, Hélène; Benoît, Yves; Bertrandfor, Yves; Children’s Leukemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC),
Informations sur la publication:Haematologica, 99, 7, page (1220-1227)
Statut de publication:Publié, 2014-07
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adolescent
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Child
Child, Preschool
Dexamethasone -- administration & dosage
Female
Humans
Immunophenotyping
Induction Chemotherapy
Infant
Infant, Newborn
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- diagnosis -- drug therapy -- mortality
Prednisolone -- administration & dosage
Risk Factors
Treatment Outcome
Langue:Anglais
Identificateurs:urn:issn:0390-6078
info:doi/10.3324/haematol.2014.103507
info:pii/haematol.2014.103507
info:pmid/24727815
PMC4077084